Recursion Pharmaceuticals Form 4 / Christopher Gibson ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Gibson Christopher

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

84101

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	12/04/2024		C⁽¹⁾⁽²⁾		20,000	A	$0	756,633	D
Class A Common Stock	12/04/2024		S⁽²⁾		20,000	D	$7.16	736,633	D
Class A Common Stock	12/05/2024		C⁽¹⁾⁽²⁾		20,000	A	$0	756,633	D
Class A Common Stock	12/05/2024		S⁽²⁾		20,000	D	$7.12	736,633	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock	$0⁽³⁾	12/04/2024		C⁽¹⁾⁽²⁾			20,000	⁽³⁾	⁽³⁾	Class A Common Stock	20,000	$0	6,036,700	D
Class B Common Stock	$0⁽³⁾	12/05/2024		C⁽¹⁾⁽²⁾			20,000	⁽³⁾	⁽³⁾	Class A Common Stock	20,000	$0	6,016,700	D
Class B Common Stock	$0							⁽³⁾	⁽³⁾	Class A Common Stock	0		486,000	I	by LAHWRAN-3 LLC⁽⁴⁾
Class B Common Stock	$0							⁽³⁾	⁽³⁾	Class A Common Stock	0		388,000	I	by LAHWRAN-4 LLC⁽⁵⁾
Class B Common Stock	$0							⁽³⁾	⁽³⁾	Class A Common Stock	0		67,875	I	by Gibson Family Trust⁽⁶⁾
Stock Option (Right to Buy)	$2.48							⁽⁷⁾	12/30/2030	Class A Common Stock	0		282,500	D
Stock Option (Right to Buy)	$8.55							⁽⁸⁾	02/01/2033	Class A Common Stock	0		813,600	D
Stock Option (Right to Buy)	$11.4							⁽⁹⁾	02/04/2032	Class A Common Stock	0		399,002	D
Stock Option (Right to Buy)	$11.4							02/04/2022	02/04/2032	Class A Common Stock	0		5,436	D
Stock Option (Right to Buy)	$10.09							⁽¹⁰⁾	02/09/2034	Class A Common Stock	0		666,898	D

Explanation of Responses:

1. Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person.

2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023.

3. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.

5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.

6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

7. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

9. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

10. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	12/06/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Recursion Pharmaceuticals (RXRX) Form 4RECURSION PHARMACEUTICALS / Christopher Gibson ownership change